1. Introduction {#sec0005}
===============

The Major Histocompatibility Complex class I (MHC-I) antigen presentation pathway plays a well-recognized role in defence against intracellular pathogens and tumors; as well as in the establishment of tolerance, autoimmunity and neuronal function ([@bib0115; @bib0100]). Almost all nucleated cells express MHC-I molecules at the cell surface where they present antigenic peptides for surveillance by cytotoxic T lymphocytes (CTLs). The CTL-mediated recognition of foreign peptides leads to killing of the infected cells. Cell surface expression of MHC-I is also closely monitored by Natural Killer (NK) cells where signals received by their killer-cell immunoglobulin-like receptors (KIRs) balance the NK-cell response between tolerance of healthy cells and killing of unhealthy ones.

Given the importance of MHC-I in the modulation of both innate and adaptive immune responses, its cell surface expression must be finely tuned. MHC-I molecules are closely regulated at each stage of the antigen-presentation pathway, including transcription, assembly of the complex in the ER, trafficking through the secretory pathway and regulated turnover at the plasma membrane ([@bib0115]).

The classical MHC-I multigene family is encoded by three loci, HLA-A, -B, and -C. How the diversity of HLA-A, -B, and -C molecules contribute to their function is incompletely understood. HLA-A and -B are well expressed on most cells and account for the majority of defined CTL epitopes, while cell surface expression of HLA-C is lower, and appears to be the dominant MHC-I in NK cell regulation ([@bib0005]). The HLA-A and -B loci have evolved separately with HLA-B evolving more rapidly than either HLA-A or -C. The principal source of HLA-B diversity arises from intralocus recombination, with less gene recombination but more point mutations seen in the HLA-A locus ([@bib0105]). HLA-B alleles play a dominant role in the control of human pathogens, particularly well described in the case of HIV whose control is influenced by the CD8 T-cell response ([@bib0070]). Selective loss of expression of alleles of the HLA-A locus ([@bib0065; @bib0045]), particularly HLA-A2, the commonest HLA allele in Caucasians, is a common feature of tumors and may facilitate CTL escape.

2. Current status {#sec0010}
=================

Much effort has focused on the transcriptional regulation of MHC-I genes, with particular emphasis on interferon (IFN) or cytokine-mediated upregulation which may be upregulated upon infection ([@bib0110; @bib0060]). Type I and II IFNs may also increase MHC-I by promoting mRNA stabilization, as demonstrated in DCs, and the IFN-γ mediated post-transcriptional regulation of individual MHC-I alleles is reported for HLA-B7 and HLA-A2 ([@bib0075]). In the case of HLA-A2, this IFN-γ mediated upregulation is due to an increase in its mRNA nuclear export ([@bib0010]).

The discovery of large numbers of non-coding RNAs and their interaction with RNA-binding proteins (RBPs) to regulate mRNA levels in key cellular processes has renewed interest in RNA metabolism. Regulation of *MHC-I* mRNA decay was first described almost two decades ago for HLA-C ([@bib0090]), and more recently *HLA-Cw\*0702* mRNA was shown to be post-transcriptionally regulated through the binding of miR-148 ([@bib0080]).

Although best recognized for its role in post-translational protein regulation, an intriguing role for ubiquitin in the regulation of RNA stability has emerged from the observations that several ubiquitin E3 ligases encode RNA binding domains (RBDs) and are therefore predicted to bind and regulate RNA ([@bib0020]). Indeed, 15 RING-containing E3 ligases possess one or more RBDs. We recently performed a functional siRNA ubiquitome screen which identified MEX-3C as a novel RNA-binding E3 ubiquitin ligase responsible for the post-transcriptional regulation of all common HLA-A allotypes, without affecting the expression of HLA-B and -C. These data suggest a novel mechanism for MHC-I allotype-specific regulation, and for the first time provide a direct link between ubiquitination and *MHC-I* mRNA decay ([@bib0025]).

3. MEX-3C mediated regulation of *HLA-A* mRNA stability in innate immunity {#sec0015}
==========================================================================

MEX-3C is a conserved RNA-binding ubiquitin E3 ligase involved in mRNA decay, and belongs to a family of four mammalian proteins (MEX-3A--D), homologues to *Caernorhabditis elegans* MEX-3 ([@bib0015]). Each member contains two tandem repeat RNA-binding KH domains and a ubiquitin E3 ligase RING domain. The founder protein, MEX-3 in *C. elegans* contains two KH domains which bind to the 3′UTR of its target mRNA *PAL-1* and inhibits its translation ([@bib0055; @bib0040]). Evolutionary diversification from *C. elegans* to *Drosophila* led to the acquisition of a C-terminal ubiquitin E3 ligase RING domain. Two further consecutive rounds of duplication from a single gene in *Drosophila* (dMex-3: RNA-binding + RING finger domain) accounts for the presence of four genes on different chromosomes in higher eukaryotes, including humans (hMEX-3A--D). Therefore, the critical question is why an RNA-binding protein involved in RNA regulation acquired E3 ligase activity? We showed that the presence of the RING was not required for translational repression of HLA-A. However, acquisition of the RING domain allows MEX-3C not only to repress HLA-A translation, but also induce *HLA-A* mRNA degradation. Hence, MEX-3 gene products were initially RNA-binding and later acquired ubiquitin E3 ligase activity, which not only prevents mRNA translation, but also promotes its degradation in a RING-dependent manner ([@bib0025]).

MEX-3C is highly expressed in cells of the innate immune system, in particular NK cells. Its expression increases upon NK cell activation as will occur when these cells enter an inflammatory environment. Increased MEX-3C expression will lead to a decrease in cell surface HLA-A levels and alter the threshold of killing by these cells. MEX-3C binds the 3′UTR of the *HLA-A* target mRNA through its RNA-binding KH domains, though the precise sequence specificity and affinity of MEX-3C has proved difficult to define and probably relates to the complex secondary structure of this region ([@bib0025]). MEX-3C shuttles with its mRNA cargo from the nucleus to the cytosol via the CRM-1 nuclear export pathway where it interacts with the Argonaute proteins AGO1 and AGO2, and is likely recruited to the RISC-mediated mRNA decay pathway ([@bib0015]). How and where the mRNA is sequestered in the absence of ubiquitin ligase activity, and which proteins are ubiquitinated to promote mRNA degradation, remains to be determined. The simplest model would suggest that after trafficking from the nucleus to the cytosol, and subsequent release from its USP7 DUB regulator ([@bib0025]), MEX-3C is autoubiquitinated and degraded, allowing the specific mRNA substrate to be transferred to the RNA degradation machinery. mRNAs are protected from decay by their 5′-CAP and the 3′ poly(A) tail. To initiate mRNA decay requires exposure of the mRNA ends, through decapping or deadenylation, to 5′-to-3′ or 3′-to-5′ exonucleases ([@bib0095]). This disassembly of mRNPs is essential to allow access of the degradation machinery to the targeted mRNA. An alternative function of MEX-3C might be to ubiquitinate components of the mRNP complex, promoting disassembly of the complex and therefore allowing access to the exonucleases.

4. Future perspectives {#sec0020}
======================

The discovery of MEX-3C and HLA-A allotype-specific regulation raises several questions. For example, what is the requirement and relevance of HLA allotype-specific regulation in the immune system, in particular NK cells? Why NK cells decrease cell surface HLA-A expression upon activation is not known, though the most plausible explanation is to reset the threshold of inhibitory receptors (e.g. KIRs, LILRs) for NK cell killing. Inhibitory receptors can bind MHC-I in *cis* (on the same cell membrane) as well as in *trans* (between opposing membranes, i.e.: on the target cell) ([@bib0035; @bib0085]). Such interactions were initially reported between murine Ly49 and MHC-I where *cis* H2D^d^ sequesters Ly49A, relieving NK cells from the inhibitory effect of unengaged Ly49A ([@bib0050; @bib0030]). Conversely, human LILRB2 (and its mouse orthologue PIRB) constitutively bind MHC-I in *cis*, causing a tonic suppression that prevents spontaneous cellular activation ([@bib0085]). The crystal structure of the LILRB1 and HLA-A2 complex revealed that LILRB1 binds HLA-A2 in *trans* as well as in *cis* ([@bib0120]). In this context, the increased levels of MEX-3C seen upon NK cell activation will cause a decrease in cell surface expression of HLA-A, freeing the potential inhibitory receptor from *cis* binding, and therefore decreasing the threshold for NK-mediated killing ([Fig. 1](#fig0005){ref-type="fig"}). This explanation is consistent with our observations that depletion of MEX-3C increases HLA-A expression and results in decreased NK cell killing ([@bib0025]). By downregulating only the HLA-A allele, activated NK cells might escape fratricide as they still express other MHC-I alleles at the cell surface. It also provides a plausible explanation for a resting tonic inhibition on NK cells, which would be unleashed as they become activated. Alternatively, MEX-3C might be required for the resolution of the inflammatory response. The downregulation of HLA-A by MEX-3C following NK activation would render NK cells susceptible to killing by neighbouring NK cells. Such a scenario does not explain the allotype-specific effect, nor the decrease in HLA-A occurring early, rather than late, during resolution of the response ([@bib0025]). Finally, low HLA-A expression may also protect NK cells against increased killing from CTLs at sites of inflammation.

It is likely that MEX-3C binds and regulates additional mRNA species. The identification of new mRNA targets will provide further insight into the function and physiological role of this novel E3 ligase, and possibly the whole family of RNA-binding E3 ligases. Expression of MEX-3C in other cell types will likely regulate a variety of cellular processes.

The identification and requirement for MHC-I allotype-specific regulation in the immune system was unanticipated and suggests either novel functions of MHC-I molecules, or differences between HLA-A and -B molecules which have not been appreciated. For example, as noted above many of the HLA associations with the control of infections are related to the HLA-B alleles, as seen in HIV, with few related to HLA-A alleles. In contrast, allotype-specific downregulation is seen in some tumors, such as malignant melanomas which selectively downregulate HLA-A2, -A28 alleles ([@bib0065]) presumably to facilitate immune evasion. Whether these observations represent major differences between HLA-A and -B alleles, or that these associations are simply non-representative is unclear. It will also be interesting to determine whether a similar level of selective regulation occurs for the HLA-B/C allotypes. Since there are at least 15 RNA-binding proteins with E3 ubiquitin ligase activity, some of these may be involved in the regulation of other MHC-I alleles. Further studies of these ligases will shed light on this novel level of regulation.

In summary, we have uncovered a novel post-transcriptional mechanism for regulating HLA-A alleles by MEX-3C. This finding links ubiquitination and *MHC-I* mRNA decay, and suggests an unanticipated requirement for the allotype-specific regulation of MHC-I molecules.

This article belongs to Special Issue on Antigen Processing and Presentation.

![MEX-3C specifically regulates HLA-A in NK cells and modulates NK cell killing. Cell surface expression of MHC-I is closely monitored by NK cells, whose activity is regulated by the balance between positive signals from activating receptors and negative signals from MHC-I recognizing inhibitory receptors. NK Inhibitory receptors can bind MHC-I in *trans* (between opposing membranes, i.e.: on the target cell), as well as in *cis* (on the same cell membrane). In naive/resting NK cells, inhibitory receptors constitutively bind MHC-I in *cis*, causing a tonic suppression that prevents spontaneous cellular activation. NK cell activation increases MEX-3C levels, which results in a decrease in surface expression of HLA-A, freeing the potential inhibitory receptor from *cis* binding, and therefore decreasing the threshold for NK-mediated killing. In this scenario, if the activated NK cell encounters a "healthy cell", the MHC-I on the target cell engages with the inhibitory receptor in *trans* resulting in no NK-mediated killing of the target cell. However, if the target cell has low expression of MHC-I, then the NK inhibitory receptor is not engaged. This relieves NK cell inhibition, causing the killing of the target cell. In the absence of MEX-3C, however, HLA-A levels on the surface of the NK cell remain high and bound in *cis* to the inhibitory receptor, resulting in a decreased level of NK-mediated killing.](gr1){#fig0005}
